Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Fig. 3

Specific antibodies against melanoma-specific self-antigens pooled in strong, weak and negative signals after merging the two cohorts. a Anti-NY-ESO-1, b anti-MelanA/MART1, c anti-TRP1/TYRP1, d anti-TRP2/TYRP2, e anti-gp100 ELISA absorbance signals were classified in “strong”, “weak” and “no response detected” by taking the mean value of the control group of cohort 1 as cutpoint for a weak positive signal and its double as cutpoint for a strong positive signal. Differences between responder (R) and non-responders (NR) were tested with Fisher’s exact test. f In addition, patients were classified according to the strongest signal obtained with any of the five antigens

Back to article page